Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

BIO and the Colorado BioScience Association urge Colorado Governor Hickenlooper to sign a bill that will help patients gain access to interchangeable biologic products following FDA approvals.

BIO Encourages Transparency with Support of Biologic Interchangeability Bill

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Drug spending rose last year at the highest rate since 2003, driven by specialty medicines, according to a report from pharmacy benefit manager Express Scripts.

Drug Spending Highest Since 2003, Says Report

Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.

Mallinckrodt Accents Critical Care With Ikaria Acquisition

The agency will employ a ring vaccination method similar to the one used to eradicate smallpox.

WHO to Launch Ebola Vaccine Efficacy Trial March 7

In a landmark decision, FDA approved Zarxio, making it the first biosimilar product in the United States.

FDA Approves First Biosimilar

Baxter has bought SuppreMol, a German biopharmaceutical company that focuses on autoimmune treatments, for €200 million ($225 million USD).

Baxter Builds Immunology Portfolio by Acquiring Autoimmune Specialist

Canon announced that it established Canon BioMedical, a wholly owned biomedical business to develop, manufacture, and market operations related to Canon’s life-science and molecular diagnostics platform.

Canon Announces New Biomedical Company

A facility expansion adds space for production of Repligen’s tangential flow system.

Repligen Expands US Manufacturing Facility

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Biosimilars may add a nice increment to the pipeline opportunities, for CMOs, but they are unlikely to be a bonanza for the industry.

Modest Expectations for CMOs and Biosimilars

Richard Grant, Global VP of Cell Therapy at Invetech discusses the advantages and challenges of developing and manufacturing personalized immunotherapies.